NRX Pharmaceuticals (NRXP) Stock Statistics & Valuation Metrics

NRX Pharmaceuticals has a market cap or net worth of $34.68M. The enterprise value is $23.57M.

NRX Pharmaceuticals has 16,915,648 shares outstanding. The number of shares has decreased by -2.65% in one year.

NRX Pharmaceuticals’s return on equity (ROE) is 1.08 and return on invested capital (ROIC) is 111.15%.

The current PE Ratio of NRX Pharmaceuticals is -0.92. NRX Pharmaceuticals’s PEG ratio is 0.02.

In the last 12 months, NRX Pharmaceuticals had revenue of 0.00 and earned -25.13M in profits. Earnings per share was -2.39.

In the last 12 months, operating cash flow was -11.27M and capital expenditures 0.00, giving a free cash flow of -11.58M billion.

NRX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

NRX Pharmaceuticals upcoming earnings date is May 20, 2025, TBA Not Confirmed.

NRX Pharmaceuticals as a current ratio of 0.15, with Debt / Equity ratio of -28.32%

In the past 12 months, NRX Pharmaceuticals has paid 0.00 in taxes.

NRX Pharmaceuticals EV to EBITDA ratio is -1.53, with an EV/FCF ratio of -2.66.

NRX Pharmaceuticals has $1.44M in cash and marketable securities with $61.00M in debt, giving a net cash position of $5.13M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for NRX Pharmaceuticals is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy